Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin to prevent immune checkpoint inhibitor-related progression of atherosclerosis
NL-OMON60766Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atherosclerosis comparing Atorvastatin + immune checkpoint inhibitor therapy with Placebo + immune checkpoint inhibitor therapy (2 arms). Primary endpoint: Annualized percentage change in non-calcified thoracic aortic plaque volume. Started Jan 2026; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NL-OMON60766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60766.